Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria
Further Perspectives and Conclusions The expanding use of GLP-1 receptor agonists offers a great deal of potential for transforming public health approaches to obesity and type 2 diabetes management
The broader picture is that the next generation of obesity treatments involves multi-target approaches, whether through single molecules activating multiple receptors (tirzepatide, retatrutide, survodutide, mazdutide) or through combination therapies pairing separate compounds (CagriSema)
More recently, it was shown that ECs act as gut chemosensory cells, similar to other EECs such as GLP-1-secreting cells, and that they form synapse-like connections with primary afferent neurons 295
While the difference was not dramatic (~3 points, which is well below the minimally clinically important difference in the MDS-UPDRS-3 of around ~5 points), it appeared to remain after a 2-month washout period, intended to support the idea that, because the improvements remained after removal of the incretin, the difference should be a disease-modifying, rather than a symptomatic benefit